Walter E. Washington Convention Center
Washington, D.C.
May 16-19, 2022

Avirmax, Inc.  

Hayward,  CA 
United States
  • Booth: 619

Avirmax , Inc. is dedicated to innovate, develop and manufacture adeno-associated virus (AAV) vector mediated biotherapeutics using its proprietary protein therapeutics and Bac-to-AAV (a VP1 enriched AAV production with baculovirus helpers in Sf9 cells) technologies. Our team of experts have worked extensively to innovate and develop AAV vectors and optimize recombinant vector production, purification and scale-up manufacturing. Using the advanced Bac-to-AAV system, allows Avirmax to quickly deliver quality cGMP material to our clients


  • AAV Manufacturing and Services
    Avirmax Services cover a full-range of offerings from molecular cloning, transgene optimization, process development through early to late-stage, clinical manufacturing, viral vector testing and regulatory submission documents...

  • The Avirmax team’s extensive experience with its unique viral vector system and many years in rAAV-based gene therapy process development, regulatory submissions for early and late clinical phases, at early and late clinical phases, provide our clients with a best-in-class service experience. Avirmax has developed robust processes to provide consistently high titers reaching 1e15 vg/L, in a shortened timeline, allowing clients to obtain quality product quickly.

    Avirmax has a full complement of industry professionals with over 85 years of experience in protein drug and gene therapy development from early-stage through to cGMP commercial manufacturing. Our service team is experienced in gene target screening, expression cassette design, codon optimization, and production of large quantities of AAV vectors.